: DGRI Financial Services for the Medical Marijuana
Business Description Dutch Gold Resources, Inc. has positioned itself in the financial and business services space, serving the Medical Marijuana industry. The Company"s goal is to establish itself as a leading provider of financial services to the sector with initial focus on merchant services, business advisory services and sponsoring state-specific crowd-funding platforms. We are a public company quoted on OTCMarkets.com under the symbol DGRI. Our strategy is to leverage technology to serve this rapidly growing sector, deploying leading edge merchant services technology, and a network of business service providers to bring credit services to support the growth of the emerging Medical Marijuana space. The Company has withdrawn from active involvement in the gold mining sector and is now a passive investor. The financial services sector in the emerging medical marijuana industry presents opportunities for growth, through the leveraging of our networks, our technology and contacts. For a stock quote and further information please click on http://www.otcmarkets.com/stock/DGRI/quote For further investor information, please click on http://www.otcmarkets.com/stock/DGRI/company-info
January 08, 2015 16:35 ET The Cannabinoid Manual Publishing Rollout Begins
Meet the Author, Dr. Michelle Reillo in a Live Webinar
ATLANTA, GA--(Marketwired - Jan 8, 2015) - Dutch Gold Resources, Inc. (OTC PINK: DGRI) (the "Company") (http://dutchgoldinc.com) today announced that its subsidiary, Ascendant Therapeutics, Inc., has completed the initial draft of its new book, The Cannabinoid Manual, by Dr. Michelle Reillo. The Company will host a webinar on Tuesday, January 13, 2015 at 2PM EST, to introduce Dr. Reillo, where she will discuss the development of the manual and how health care professionals and consumers might use the book.
The Manual is based on over 1,500 peer reviewed scientific papers and presents leading edge information on the impact of Cannabidiol on health and healing. Covering more than two-dozen diseases, the manual discusses the effect of Cannabidiol supplementation on the endocannabinoid system in the human body. Over 1,100,000 people use medical marijuana every month many without a clear understanding of cannabinoids. (Source http://medicalmarijuana.procon.org/...esource.php?resourceID=005889). The Company believes that the market for CBD products exceeds 15,000,000 prospects. This manual represents the first true compilation of the scientific data generated over the last twenty years, up to now.
Said Dr. Reillo, "The Cannabinoid Manual illuminates the newly discovered endocannabinoid system as the central physiological conductor of homeostasis. The exploration of how cannabinoid receptors and phytocannabinoids interact in disease processes and the possibilities for prevention and medical management of disorders utilizing adjunctive Cannabidiol (CBD ) from legal industrial hemp is critical for all health care practitioners, including physicians, nurse practitioners, nurses, chiropractors, and dentists."
The webinar event may be accessed by registering at http://webinarjam.net/webinar/go/13700/27e47b98b0. This webinar focuses on the potential uses of CBD and health and is appropriate for both healthcare professionals and consumers. Interested investors are urged to attend, as an update on the publishing of the manual will be discussed as well as other corporate developments. We encourage everyone to attend. Our goal is to bring this important information to as many people as possible, to help improve the health of any many as possible.
Forward-Looking Statements This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Dutch Gold Resources, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.